Amplia Therapeutics Secures U.S. Patent Protection for FAK Inhibitor Narmafotinib Through 2040
核心洞察
Amplia Therapeutics (搜索) received a Certificate of Grant from the US Patent and Trademark Office for a key patent protecting the specific form of narmafotinib, extending protection to at least 2040.
The patent titled "A salt and crystal form of a FAK (搜索) Inhibitor" has already been granted in Europe, Japan, India, Korea and Australia, strengthening the company's intellectual property portfolio.
Narmafotinib is currently being tested in the ACCENT trial for advanced pancreatic cancer (搜索), where it achieved a 33% confirmed response rate superior to the 23% benchmark for standard chemotherapy alone.
Amplia Therapeutics (搜索) Limited announced it has received formal notification from the US Patent and Trademark Office (USPTO) that a key patent for its FAK (搜索) inhibitor narmafotinib has been granted. The Certificate of Grant extends protection for the drug candidate to at least 2040 in the United States and other major pharmaceutical markets.
Patent Protection Strengthens Intellectual Property Portfolio
The granted patent, titled "A salt and crystal form of a FAK (搜索) Inhibitor," protects the specific form of narmafotinib being developed clinically by the Australian pharmaceutical company. The patent has already been secured in various important jurisdictions including Europe, Japan, India, Korea and Australia, with protection in other regions currently under review by respective patent offices.
"With the granting of this patent in the US and other key pharmaceutical markets, we are strengthening narmafotinib's patent portfolio to protect and maximize the Company's intellectual property for the long term," said Amplia CEO Dr Chris Burns.
Clinical Development in Pancreatic Cancer
Narmafotinib (AMP945) is Amplia's best-in-class inhibitor of the protein FAK (搜索), which is over-expressed in pancreatic cancer (搜索) and represents a drug target gaining increasing attention for its role in solid tumors. The highly potent and selective FAK inhibitor has demonstrated promising data across a range of preclinical cancer studies.
The drug is currently undergoing clinical evaluation in the ACCENT trial, where it is administered in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer (搜索). The trial has already achieved its primary endpoint with a confirmed response rate of 33%, which is superior to the 23% reported in the benchmark MPACT study for gemcitabine and Abraxane alone. An interim median progression-free survival of 7.6 months has also been reported.
Expanding Clinical Program
Amplia has recently opened a second trial called AMPLICITY, which is being conducted under an IND at sites in Australia and the US. This study is investigating the combination of narmafotinib with the chemotherapy regimen FOLFIRINOX in advanced pancreatic cancer (搜索) patients.
Therapeutic Focus on FAK Inhibition
Amplia Therapeutics (搜索) is advancing a pipeline of Focal Adhesion Kinase (FAK (搜索)) inhibitors for cancer and fibrosis applications. The company has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer (搜索). FAK also plays a significant role in chronic diseases, including idiopathic pulmonary fibrosis (搜索) (IPF), representing an increasingly important target in oncology and beyond.